2. Academic Validation
  3. The syntheses of isotopically labelled CB-1 antagonists for the treatment of obesity

The syntheses of isotopically labelled CB-1 antagonists for the treatment of obesity

  • J Labelled Comp Radiopharm. 2016 Dec;59(14):665-672. doi: 10.1002/jlcr.3433.
Scott B Tran 1,  Brad D Maxwell 1,  Richard Burrell 2,  Samuel J Bonacorsi Jr 1
Affiliations

Affiliations

  • 1 Discovery Chemistry Platforms - Radiochemistry, Bristol-Myers Squibb, Inc, P.O. Box 4000, Princeton, NJ, 08543, USA.
  • 2 Discovery Chemistry Platforms - Radiochemistry, Bristol-Myers Squibb, Inc, P.O. Box 5100, Wallingford, CT, 06492, USA.
PMID: 27624665 DOI: 10.1002/jlcr.3433
Abstract

BMS-725519, BMS-811064, and BMS-812204 are potent and selective central Cannabinoid Receptor antagonists that have been investigated for the treatment of human obesity. To further understand their biotransformation profiles, radiolabelled and stable-labelled products were required. This paper describes the utility of [14 C]1,1-carbonyldiimidazole as a radiolabelling reagent for the syntheses of carbonyl-labelled [14 C]BMS-725519, [14 C]BMS-811064, and [14 C]BMS-812204. The syntheses of stable-labelled [13 C6 ]BMS-725519 and [13 CD313 CD2 ]BMS-812204 synthesized from of [13 C6 ]4-chloroacetophenone and [13 CD313 CD2 ]iodoethane, respectively, are also described.

Keywords

CB-1 antagonists; carbon-13; deuterium; synthesis.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z